# ADD Tech Mahindra

# In-line performance; delivery execution off to a steady start

Information Technology > Result Update > July 26, 2024

Tech Mahindra (TechM) reported a broadly in-line operating performance. Revenue inched up 0.7% QoQ to US\$1.56bn, largely meeting our estimates. Growth was fairly broad-based, with 5 of the 7 verticals seeing QoQ growth (decline in Communications due to Comviva seasonality). EBITM of 8.5% was also in line with our estimate, with headwinds from Comviva seasonality and higher visa costs offset by benefits accrued from Project Fortius. The management highlighted that its 'speed at scale' strategy is being well received by clients, and reiterated that FY25 should be better than FY24. The demand environment has remained fairly similar to last quarter's, albeit seeing some improvement versus previous year. With the company's delivery execution to achieve its 'Vision 2027' strategy off to a solid start, we hike up our target multiple to 22x (from 19x). We tweak FY25-27E EPS by -2% to +2%, factoring in the Q1 performance and higher ETR assumptions. We maintain ADD and raise our TP to Rs1,650/sh (from Rs1,425 earlier) at 22x Jun-26E EPS.

Tech Mahindra: Financial Snapshot (Consolidated)								
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E			
Revenue	532,902	519,956	534,492	590,345	654,263			
EBITDA	80,288	49,645	74,328	98,959	116,216			
Adj. PAT	48,313	23,578	42,759	62,050	75,007			
Adj. EPS (Rs)	54.9	26.7	48.4	70.2	84.9			
EBITDA margin (%)	15.1	9.5	13.9	16.8	17.8			
EBITDA growth (%)	0.1	(38.2)	49.7	33.1	17.4			
Adj. EPS growth (%)	(13.4)	(51.3)	81.1	45.1	20.9			
RoE (%)	18.5	10.3	15.8	21.9	24.8			
RoIC (%)	22.8	12.0	20.8	30.1	36.0			
P/E (x)	27.9	57.3	31.6	21.8	18.0			
EV/EBITDA (x)	16.0	25.9	17.3	12.8	10.7			
P/B (x)	4.8	5.1	4.9	4.6	4.3			
FCFF yield (%)	3.4	4.2	2.9	4.6	5.5			

Source: Company, Emkay Research

### **Results Summary**

Revenue grew 0.7% QoQ (0.7% in CC) to US\$1.56bn, broadly in line with our estimates. Revenue for IT Services and BPS verticals grew 0.6% and 1.3% QoQ on like-to-like basis. Five of the 7 verticals saw sequential growth, with Manufacturing (2.4% QoQ), Hi-Tech and Media (0.5%), BFSI (0.7%), Retail, Transportation and Logistics (5.2%), and Healthcare and Lifesciences (7.9%) seeing growth. Communications and Others declined 1.9% and 5.2% QoQ, respectively. Among geographies, Americas grew 3.9% QoQ, while Europe and ROW declined 2.6% and 2.7%, respectively. Adj. EBITM expanded by 110bps to 8.5%, broadly in line with our estimate of 8.3%. Net new deal wins remained steady at US\$534mn. Total headcount grew 1.5% QoO/-0.5% YoY to 147,620, with the inclusion of ~2,100 interns among BPO professionals resulting in QoQ growth. Attrition was stable at 10.1% (vs 10% in Q4FY24). What we liked: Steady operating performance and deal intake. What we did not like: Weak cash conversion (~64% OCF/ EBITDA).

### **Earnings Call KTAs**

i) Performance was led by broad-based growth across verticals except Communications, which remains subdued. The management indicated that Comviva seasonality impacted revenue and margin by 50bps. TechM continues to focus on execution and is on track to achieve its stated goals for FY27. ii) BFSI demand trend has been stable, with improvement in US spending across asset and wealth management, cards, and payments, while investment banking and lending remain soft. The management sees new opportunities in existing accounts and addition of new logos; however, it expects some volatility in performance in the near term, considering the smaller footprint. iii) Telecom continues to face challenges, but the decline has reduced to a single digit and the company expects YoY improvement in coming quarters. iv) The management believes levers are in place for margin improvement, with building the employee pyramid as the major driver over the medium term. It added ~1,000 freshers in Q1. Project Fortius aids ~120bps margin improvement during the quarter. v) The management has no plans of wage hikes in FY25 for now, and will re-evaluate this stance in H2. vi) TechM launched TECHM Verify during the quarter, focusing on the validation and assurance framework for AI systems, thus addressing the missing link in wide-scale AI adoption. vii) The management shared that over 25,000 associates have been trained with AI skills and the company now offers over 100 AI-based solutions. viii) The management indicated that contact-center dependency is <5% of revenue at the company level.



### **TARGET PRICE (Rs): 1,650**

Target Price – 12M	Jun-25
Change in TP (%)	15.8
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	7.8
CMP (25-Jul-24) (Rs)	1,530.0
Stock Data	Ticker
52-week High (Rs)	1,548
52-week Low (Rs)	1,082
Shares outstanding (mn)	977.9
Market-cap (Rs bn)	1,496
Market-cap (USD mn)	17,875
Net-debt, FY25E (Rs mn)	-69,162
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	3,440.4
ADTV-3M (USD mn)	41.1
Free float (%)	64.0
Nifty-50	24,406
INR/USD	83.7
Shareholding, Jun-24	

<b>5</b> , <b>5</b> , <b>1</b>	
Promoters (%)	35.1
FPIs/MFs (%)	23.3/30.8

Price Performance							
(%)	1M	3M	12M				
Absolute	7.2	28.5	32.3				
Rel. to Nifty	4.2	18.9	6.7				



#### Dipesh Mehta

dipeshkumar.mehta@emkavalobal.com +91 22 6612 1253

### Ayush Bansal

ayush.bansal@emkayglobal.com +91 22 6612 1344

#### Pulkit Chawla

pulkit.chawla@emkayglobal.com +91 22 6642 4258

## Exhibit 1: Quarterly snapshot

(Rs mn)	Q1FY25	Q4FY24	QoQ(%)	Q1FY24	YoY (%)
Revenue (US\$ mn)	1,559	1,548	0.7	1,601	-2.6
Net sales	130,055	128,713	1.0	131,590	-1.2
Total Income	130,055	128,713	1.0	131,590	
Operating expenses	114,410	114,635		118,210	
EBITDA	15,645	14,078	11.1	13,380	16.9
Margin (%)	12.0	10.9	110	10.2	190
Depreciation	4,622	4,614		4,466	
EBIT	11,023	9,464	16.5	8,914	23.7
Margin (%)	8.5	7.4	110	6.8	170
Interest	(715)	(585)		(1,197)	
Other income	1,447	3,735		1,917	
Pre-tax profit	11,755	12,614	-6.8	9,634	22.0
Tax provided	3,133	2,949		2,676	
Profit after tax	8,622	9,665	-10.8	6,958	23.9
MI	(107)	32		(33)	
Reported Profit After tax	8,515	6,610	28.8	6,925	23.0
Emkay Net Profit	8,515	9,697	-12.2	6,925	23.0
EPS (Rs)	9.6	11.0	-12.3	7.9	22.5

Source: Company, Emkay Research

### Exhibit 2: Actuals vs estimates

		Estimate		% varia		Comment
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	
Revenue (US\$ mn)	1,559	1,557	1,552	0.1%	0.4%	Revenue growth was in line with expectations.
Sales	130,055	129,867	129,493	0.1%	0.4%	
EBIT	11,023	10,813	10,359	1.9%	6.4%	EBITM came a tad better than expectations.
EBIT margin	8.5%	8.3%	8.0%	10 bps	50 bps	
Profit	8,515	8,636	8,676	-1.4%	-1.9%	Profit missed expectations due to higher ETR.

Source: Company, Bloomberg, Emkay Research

### Exhibit 3: Changes in estimates

	FY25E			FY26E			FY27E		
(Rs mn)	Old	New	Change	Old	New	Change	Old	New	Change
Revenues (US\$ mn)	6,360	6,374	0.2%	6,934	6,945	0.2%	7,559	7,608	0.6%
YoY growth	1.3%	1.5%		9.0%	9.0%		9.0%	9.5%	
Revenue	533,344	534,492	0.2%	589,428	590,345	0.2%	650,091	654,263	0.6%
EBIT	55,058	55,385	0.6%	79,459	79,614	0.2%	94,934	95,680	0.8%
EBITM (%)	10.3	10.4		13.5	13.5		14.6	14.6	
Net Profit	43,517	42,759	-1.7%	62,472	62,050	-0.7%	74,029	75,007	1.3%
EPS (Rs)	49.3	48.4	-1.9%	70.8	70.2	-0.8%	83.9	84.9	1.2%

Source: Company, Emkay Research





Source: Company, Emkay Research

This report is intended for team emkay @wbitemarguesolutions com use and downloaded at 08/15/2024 03:36 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **Tech Mahindra: Consolidated Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	532,902	519,956	534,492	590,345	654,263
Revenue growth (%)	19.4	(2.4)	2.8	10.4	10.8
EBITDA	80,288	49,645	74,328	98,959	116,216
EBITDA growth (%)	0.1	(38.2)	49.7	33.1	17.4
Depreciation & Amortization	19,567	18,171	18,944	19,345	20,536
EBIT	60,721	31,474	55,385	79,614	95,680
EBIT growth (%)	(6.6)	(48.2)	76.0	43.7	20.2
Other operating income	0	0	0	0	0
Other income	9,650	9,169	6,335	7,268	8,618
Financial expense	3,256	3,922	2,967	3,057	3,081
РВТ	67,115	36,721	58,754	83,826	101,218
Extraordinary items	(2,370)	(4,582)	0	0	0
Taxes	15,885	8,276	15,588	21,376	25,811
Minority interest	(547)	(285)	(407)	(400)	(400)
Income from JV/Associates	0	0	0	0	0
Reported PAT	48,313	23,578	42,759	62,050	75,007
PAT growth (%)	(13.2)	(51.2)	81.4	45.1	20.9
Adjusted PAT	48,313	23,578	42,759	62,050	75,007
Diluted EPS (Rs)	54.9	26.7	48.4	70.2	84.9
Diluted EPS growth (%)	(13.4)	(51.3)	81.1	45.1	20.9
DPS (Rs)	50.0	40.0	40.0	50.0	60.0
Dividend payout (%)	91.0	149.7	82.7	71.2	70.7
EBITDA margin (%)	15.1	9.5	13.9	16.8	17.8
EBIT margin (%)	11.4	6.1	10.4	13.5	14.6
Effective tax rate (%)	23.7	22.5	26.5	25.5	25.5
NOPLAT (pre-IndAS)	46,349	24,381	40,691	59,313	71,282
Shares outstanding (mn)	879.9	882.5	883.6	883.6	883.6

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	4,400	4,413	4,418	4,418	4,418
Reserves & Surplus	274,845	262,281	269,694	287,562	309,550
Net worth	279,245	266,694	274,112	291,980	313,969
Minority interests	4,702	4,774	4,774	4,774	4,774
Deferred tax liability (net)	(9,704)	(11,651)	(11,651)	(11,651)	(11,651)
Total debt	14,858	14,606	14,473	14,473	14,473
Total liabilities & equity	289,101	274,423	281,708	299,576	321,565
Net tangible fixed assets	28,622	25,577	23,065	22,276	21,471
Net intangible assets	33,425	29,063	23,568	18,507	13,534
Net ROU assets	10,972	9,605	7,897	6,853	5,274
Capital WIP	836	1,011	1,000	1,000	1,000
Goodwill	76,657	75,106	75,106	75,106	75,106
Investments [JV/Associates]	0	0	0	0	C
Cash & equivalents	76,428	79,732	83,635	101,168	122,211
Current assets (ex-cash)	221,628	199,746	211,623	229,076	249,048
Current Liab. & Prov.	159,467	145,417	144,187	154,410	166,080
NWC (ex-cash)	62,161	54,329	67,437	74,666	82,968
Total assets	289,101	274,423	281,708	299,576	321,565
Net debt	(61,570)	(65,126)	(69,162)	(86,695)	(107,738)
Capital employed	289,101	274,423	281,708	299,576	321,565
Invested capital	211,837	193,680	197,073	197,408	198,354
BVPS (Rs)	317.4	302.2	310.2	330.4	355.3
Net Debt/Equity (x)	(0.2)	(0.2)	(0.3)	(0.3)	(0.3)
Net Debt/EBITDA (x)	(0.8)	(1.3)	(0.9)	(0.9)	(0.9)
Interest coverage (x)	0.0	0.1	0.0	0.0	0.0
RoCE (%)	24.5	14.4	22.2	29.9	33.6

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
РВТ	67,115	36,721	58,754	83,826	101,218
Others (non-cash items)	29,647	31,002	18,537	18,945	20,136
Taxes paid	(19,931)	(12,469)	(15,588)	(21,376)	(25,811)
Change in NWC	(18,451)	12,987	(13,108)	(7,229)	(8,302)
Operating cash flow	55,720	63,764	48,595	74,165	87,241
Capital expenditure	(9,692)	(7,377)	(9,218)	(12,450)	(13,180)
Acquisition of business	(10,672)	(7,488)	0	0	0
Interest & dividend income	1,448	1,531	0	0	0
Investing cash flow	(2,785)	(13,137)	(26,424)	(12,450)	(13,180)
Equity raised/(repaid)	442	238	5	0	0
Debt raised/(repaid)	(1,594)	(688)	(133)	0	0
Payment of lease liabilities	(4,426)	(4,545)	0	0	0
Interest paid	(2,570)	(3,507)	0	0	0
Dividend paid (incl tax)	(42,633)	(39,170)	(35,346)	(44,182)	(53,019)
Others	0	0	0	0	0
Financing cash flow	(50,781)	(47,672)	(35,474)	(44,182)	(53,019)
Net chg in Cash	2,154	2,955	(13,303)	17,533	21,043
OCF	55,720	63,764	48,595	74,165	87,241
Adj. OCF (w/o NWC chg.)	74,171	50,777	61,702	81,395	95,543
FCFF	46,028	56,387	39,377	61,715	74,061
FCFE	44,220	53,996	36,410	58,658	70,981
OCF/EBITDA (%)	69.4	128.4	65.4	74.9	75.1
FCFE/PAT (%)	91.5	229.0	85.2	94.5	94.6
FCFF/NOPLAT (%)	99.3	231.3	96.8	104.1	103.9

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	27.9	57.3	31.6	21.8	18.0
P/CE(x)	19.2	29.1	21.9	16.6	14.2
P/B (x)	4.8	5.1	4.9	4.6	4.3
EV/Sales (x)	2.4	2.5	2.4	2.1	1.9
EV/EBITDA (x)	16.0	25.9	17.3	12.8	10.7
EV/EBIT(x)	21.2	40.8	23.2	15.9	13.0
EV/IC (x)	6.1	6.6	6.5	6.4	6.3
FCFF yield (%)	3.4	4.2	2.9	4.6	5.5
FCFE yield (%)	3.3	4.0	2.7	4.3	5.3
Dividend yield (%)	3.3	2.6	2.6	3.3	3.9
DuPont-RoE split					
Net profit margin (%)	9.5	5.4	8.0	10.5	11.5
Total asset turnover (x)	1.9	1.8	1.9	2.0	2.1
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	18.5	10.3	15.8	21.9	24.8
DuPont-RoIC					
NOPLAT margin (%)	8.7	4.7	7.6	10.0	10.9
IC turnover (x)	2.6	2.6	2.7	3.0	3.3
RoIC (%)	22.8	12.0	20.8	30.1	36.0
Operating metrics					
Core NWC days	42.6	38.1	46.1	46.2	46.3
Total NWC days	42.6	38.1	46.1	46.2	46.3
Fixed asset turnover	7.1	6.9	7.1	7.9	8.7
Opex-to-revenue (%)	84.9	90.5	86.1	83.2	82.2

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 08/15/2024 03:36 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-24	1,472	1,425	Add	Dipeshkumar Mehta
10-Jun-24	1,340	1,350	Add	Dipeshkumar Mehta
09-Jun-24	1,378	1,350	Add	Dipeshkumar Mehta
03-Jun-24	1,245	1,350	Add	Dipeshkumar Mehta
27-May-24	1,330	1,350	Add	Dipeshkumar Mehta
26-Apr-24	1,279	1,350	Add	Dipeshkumar Mehta
31-Mar-24	1,248	1,450	Add	Dipeshkumar Mehta
01-Mar-24	1,272	1,450	Add	Dipeshkumar Mehta
25-Jan-24	1,322	1,450	Add	Dipeshkumar Mehta
31-Dec-23	1,273	1,450	Add	Dipeshkumar Mehta
30-Nov-23	1,221	1,330	Add	Dipeshkumar Mehta
25-Oct-23	1,142	1,330	Buy	Dipeshkumar Mehta
02-Oct-23	1,223	1,360	Buy	Dipeshkumar Mehta
26-Jul-23	1,143	1,200	Buy	Dipeshkumar Mehta
02-Jul-23	1,131	1,200	Buy	Dipeshkumar Mehta
28-Apr-23	1,024	1,170	Buy	Dipeshkumar Mehta
01-Apr-23	1,102	1,270	Buy	Dipeshkumar Mehta
11-Mar-23	1,061	1,270	Buy	Dipeshkumar Mehta
04-Mar-23	1,085	1,270	Buy	Dipeshkumar Mehta
30-Jan-23	1,036	1,220	Buy	Dipeshkumar Mehta
02-Jan-23	1,010	1,220	Buy	Dipeshkumar Mehta
02-Dec-22	1,115	1,200	Buy	Dipeshkumar Mehta
04-Oct-22	1,028	1,200	Buy	Dipeshkumar Mehta
25-Jul-22	1,017	1,240	Buy	Dipeshkumar Mehta
23-Jun-22	991	1,260	Buy	Dipeshkumar Mehta
14-May-22	1,203	1,600	Buy	Dipeshkumar Mehta
01-Apr-22	1,487	1,730	Buy	Dipeshkumar Mehta
22-Feb-22	1,413	1,730	Buy	Dipeshkumar Mehta
02-Feb-22	1,483	1,900	Buy	Dipeshkumar Mehta
18-Jan-22	1,661	1,930	Buy	Dipeshkumar Mehta
01-Jan-22	1,791	1,930	Buy	Dipeshkumar Mehta
30-Nov-21	1,541	1,930	Buy	Dipeshkumar Mehta
11-Nov-21	1,522	1,870	Buy	Dipeshkumar Mehta
25-Oct-21	1,524	1,870	Buy	Dipeshkumar Mehta
02-Oct-21	1,371	1,700	Buy	Dipeshkumar Mehta
27-Aug-21	1,445	1,700	Buy	Dipeshkumar Mehta
29-Jul-21	1,128	1,480	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/15/2024 03:36 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/15/2024 03:36 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup>An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of July 26, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of July 26, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the July 26, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/15/2024 03:36 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### **OTHER DISCLAIMERS AND DISCLOSURES:**

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.